Heinz Weidenthaler | Director Pharmacovigilance, QPPV
Bavarian Nordic

Heinz Weidenthaler, Director Pharmacovigilance, QPPV, Bavarian Nordic

Heinz Weidenthaler graduated in medicine in 2000, and holds a M.D. degree since 2003. Initial clinical training in psychiatry, then started in the pharmaceutical industry in 2002, when he joined Novartis (Nuremberg, Germany) as Medical Safety Expert. He worked there until 2009 in the German country affiliate, including team lead for respiratory and psychiatric products, additional roles as Safety Responsible Person for Medical Devices and local manager for implementation of Risk Management Plans. In 2009, he took over as QPPV and Director Pharmacovigilance at Medigene AG in Martinsried, Germany, where he was responsible for all pharmacovigilance aspects of marketed and development products. Since 2013 he is QPPV and Director Pharmacovigilance at Bavarian Nordic GmbH, Martinsried, Germany. Responsibility includes pharmacovigilance for vaccines for infectious diseases and tumor vaccines, approved and under clinical development.


Day Two World Drug Safety Congress EU 2018 @ 14:25

PV challenges for developing vaccines for rare diseases

  • Considerations about target populations, healthy vs. ill subjects
  • Benefit-risk assessment in low-incidence diseases
  • Ethical aspects for vaccine trials in special populations, such as paediatrics and elderly subjects
last published: 13/Aug/18 10:55 GMT

back to speakers